The latest research also confirmed that the BDNF gene therapy was a promising method for the treatment of AD according to a phase I clinical trial of aav2-BDNF gene therapy for early Alzheimer's disease and mild cognitive impairment, which protects against tau-related neurodegeneration of Alzheimer's disease [78]. The gene discussed is MAPT; the disease is Alzheimer disease.